Aminopyrimidinone cdc7 kinase inhibitors

Area of Science:

• Medicinal Chemistry
• Molecular Biology
• Drug Discovery

Background:

• Cdc7 kinase is a key regulator of DNA replication.
• Dysregulation of Cdc7 kinase is implicated in various cancers.
• Developing selective Cdc7 kinase inhibitors is a therapeutic goal.

Purpose of the Study:

• To investigate the Structure-Activity Relationship (SAR) of pyrimidinone-based compounds targeting Cdc7 kinase.
• To identify potent and selective inhibitors of Cdc7 kinase.

Main Methods:

• Synthesis of a series of pyrimidinone-containing compounds.
• Evaluation of inhibitory activity (K(i)) against Cdc7 kinase.
• Assessment of kinase selectivity.
• Measurement of cytotoxicity and correlation with MCM2 phosphorylation inhibition.

Main Results:

• A wide range of amine substitutions on the pyrimidinone core yielded potent inhibitors.
• Several compounds exhibited inhibitory activities (K(i)) below 1 nM.
• The inhibitors demonstrated reasonable selectivity across kinases.
• Cytotoxicity of the compounds correlated directly with the inhibition of MCM2 phosphorylation.

Conclusions:

• Pyrimidinone derivatives represent a promising scaffold for the development of potent Cdc7 kinase inhibitors.
• The SAR study identified key substitutions for optimizing potency and selectivity.
• Inhibition of MCM2 phosphorylation serves as a relevant biomarker for the efficacy of these inhibitors.